Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adjuvant procarbazine, CCNU and vincristine chemotherapy in patients with highly anaplastic oligodendroglioma (in collaboration with the EORTC).

Next Previous
X
Search
Trial Profile

Adjuvant procarbazine, CCNU and vincristine chemotherapy in patients with highly anaplastic oligodendroglioma (in collaboration with the EORTC).

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lomustine; Procarbazine; Vincristine
  • Indications Astrocytoma; Glioma
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use

    • Most Recent Events

    • 31 May 2013 Results of a pharmacogenomic analysis (n=115) presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
    • 15 Oct 2012 Long-term follow-up results (median 140 months) published in the Journal of Clinical Oncology.
    • 15 Oct 2012 Primary endpoint 'Overall-survival-duration' has been met according to long-term analysis of results published in the Journal of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top